 Carlton Barnett
Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 5 | 2020 | 215 | 2.090 |
Why?
| | Pancreatic Neoplasms | 10 | 2013 | 731 | 2.060 |
Why?
| | Adenocarcinoma | 8 | 2020 | 795 | 1.600 |
Why?
| | Intercellular Adhesion Molecule-1 | 7 | 2013 | 154 | 1.600 |
Why?
| | Erythrocyte Transfusion | 6 | 2013 | 189 | 1.470 |
Why?
| | Liver Neoplasms | 4 | 2020 | 506 | 1.390 |
Why?
| | Neutrophils | 13 | 2017 | 1176 | 1.310 |
Why?
| | Plasma | 4 | 2013 | 211 | 1.100 |
Why?
| | Hyperthermia, Induced | 2 | 2021 | 65 | 0.900 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 430 | 0.780 |
Why?
| | Cytokines | 4 | 2013 | 1840 | 0.750 |
Why?
| | Burns, Electric | 1 | 2020 | 20 | 0.710 |
Why?
| | Transfusion Reaction | 2 | 2010 | 65 | 0.680 |
Why?
| | Microwaves | 1 | 2019 | 31 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 858 | 0.600 |
Why?
| | Liver | 2 | 2020 | 1637 | 0.590 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 327 | 0.580 |
Why?
| | Blood Preservation | 2 | 2012 | 263 | 0.580 |
Why?
| | Macrophages | 4 | 2013 | 1261 | 0.580 |
Why?
| | Surgical Flaps | 2 | 2016 | 121 | 0.550 |
Why?
| | Ileocecal Valve | 1 | 2016 | 4 | 0.540 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 31 | 0.530 |
Why?
| | Colectomy | 1 | 2016 | 86 | 0.500 |
Why?
| | Pancreaticojejunostomy | 1 | 2015 | 5 | 0.490 |
Why?
| | Duodenum | 1 | 2015 | 62 | 0.480 |
Why?
| | Multiple Organ Failure | 5 | 2011 | 146 | 0.440 |
Why?
| | Disease Progression | 6 | 2020 | 2380 | 0.440 |
Why?
| | Crohn Disease | 1 | 2016 | 196 | 0.420 |
Why?
| | Blood Substitutes | 1 | 2013 | 27 | 0.420 |
Why?
| | Pancreas | 1 | 2015 | 276 | 0.410 |
Why?
| | Neoplasm Metastasis | 3 | 2013 | 523 | 0.410 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 2710 | 0.400 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2020 | 498 | 0.400 |
Why?
| | Blood Loss, Surgical | 2 | 2010 | 84 | 0.400 |
Why?
| | Mice | 12 | 2020 | 14863 | 0.390 |
Why?
| | Hematocrit | 1 | 2012 | 87 | 0.390 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 520 | 0.370 |
Why?
| | Hemoglobins | 1 | 2013 | 315 | 0.360 |
Why?
| | Osteomyelitis | 2 | 2009 | 105 | 0.360 |
Why?
| | Hernia, Abdominal | 1 | 2010 | 6 | 0.350 |
Why?
| | Interleukin-6 | 5 | 1996 | 676 | 0.350 |
Why?
| | Peritoneum | 1 | 2010 | 36 | 0.350 |
Why?
| | Hepatectomy | 2 | 2008 | 119 | 0.350 |
Why?
| | Surgical Mesh | 1 | 2010 | 40 | 0.340 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 78 | 0.340 |
Why?
| | Neoplasms | 2 | 2017 | 2097 | 0.330 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 4692 | 0.320 |
Why?
| | Blood Platelets | 2 | 2012 | 351 | 0.320 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 111 | 0.320 |
Why?
| | Pancreaticoduodenectomy | 1 | 2010 | 133 | 0.320 |
Why?
| | Hemipelvectomy | 1 | 2008 | 1 | 0.320 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 615 | 0.310 |
Why?
| | Animals | 17 | 2020 | 31698 | 0.310 |
Why?
| | Fires | 2 | 2019 | 73 | 0.310 |
Why?
| | Operating Rooms | 2 | 2019 | 86 | 0.310 |
Why?
| | Pressure Ulcer | 1 | 2008 | 31 | 0.310 |
Why?
| | Critical Care | 1 | 2012 | 476 | 0.300 |
Why?
| | Platelet Transfusion | 1 | 2008 | 64 | 0.290 |
Why?
| | Critical Illness | 1 | 2012 | 645 | 0.280 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 281 | 0.270 |
Why?
| | Neoplasm Invasiveness | 4 | 2013 | 442 | 0.260 |
Why?
| | Laparoscopy | 1 | 2010 | 398 | 0.260 |
Why?
| | Teaching | 1 | 2008 | 213 | 0.260 |
Why?
| | Macrophage Activation | 2 | 2020 | 164 | 0.260 |
Why?
| | Sex Characteristics | 1 | 2010 | 640 | 0.250 |
Why?
| | Humans | 39 | 2021 | 114662 | 0.240 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3532 | 0.230 |
Why?
| | Superoxides | 5 | 1998 | 214 | 0.220 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2001 | 81 | 0.210 |
Why?
| | Platelet Activating Factor | 4 | 1999 | 90 | 0.210 |
Why?
| | Wounds and Injuries | 3 | 2012 | 749 | 0.190 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 228 | 0.190 |
Why?
| | Phospholipases A | 1 | 2001 | 101 | 0.180 |
Why?
| | Arginase | 1 | 2020 | 27 | 0.180 |
Why?
| | Perioperative Care | 1 | 2021 | 127 | 0.180 |
Why?
| | Leukocyte Elastase | 2 | 1997 | 79 | 0.170 |
Why?
| | Immunocompetence | 1 | 2019 | 40 | 0.170 |
Why?
| | Aftercare | 1 | 2021 | 186 | 0.170 |
Why?
| | Electrosurgery | 1 | 2019 | 43 | 0.160 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 19 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 268 | 0.160 |
Why?
| | Thoracic Injuries | 1 | 1999 | 55 | 0.160 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 34 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 249 | 0.160 |
Why?
| | Internship and Residency | 1 | 2008 | 926 | 0.160 |
Why?
| | Apoptosis | 3 | 1996 | 2362 | 0.150 |
Why?
| | Smoke | 1 | 2019 | 123 | 0.150 |
Why?
| | CD18 Antigens | 1 | 1998 | 33 | 0.150 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 275 | 0.150 |
Why?
| | Endopeptidases | 1 | 1998 | 71 | 0.150 |
Why?
| | Female | 17 | 2019 | 59493 | 0.150 |
Why?
| | Sex Factors | 2 | 2015 | 1715 | 0.150 |
Why?
| | Carbon Dioxide | 1 | 2019 | 218 | 0.150 |
Why?
| | Peritoneal Neoplasms | 2 | 2010 | 54 | 0.150 |
Why?
| | Injury Severity Score | 3 | 2015 | 499 | 0.140 |
Why?
| | Pancreatic Elastase | 2 | 1999 | 66 | 0.140 |
Why?
| | Patient Care Team | 1 | 2021 | 517 | 0.140 |
Why?
| | Isoproterenol | 1 | 1997 | 106 | 0.140 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 207 | 0.140 |
Why?
| | General Surgery | 2 | 2009 | 127 | 0.140 |
Why?
| | Hemostasis, Surgical | 2 | 2008 | 19 | 0.140 |
Why?
| | Breast Neoplasms | 1 | 2008 | 1862 | 0.140 |
Why?
| | Inflammation Mediators | 1 | 1999 | 477 | 0.140 |
Why?
| | Cell Death | 1 | 1998 | 322 | 0.140 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 127 | 0.140 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 126 | 0.130 |
Why?
| | Erythrocytes | 2 | 2012 | 591 | 0.130 |
Why?
| | Calcium | 2 | 2001 | 1108 | 0.130 |
Why?
| | Male | 16 | 2019 | 55583 | 0.130 |
Why?
| | Interleukin-8 | 1 | 1996 | 237 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 574 | 0.130 |
Why?
| | Ethanol | 1 | 2019 | 538 | 0.120 |
Why?
| | Patient Discharge | 1 | 2021 | 772 | 0.120 |
Why?
| | Chimerism | 1 | 2015 | 28 | 0.120 |
Why?
| | Skin | 1 | 2019 | 655 | 0.120 |
Why?
| | Down-Regulation | 2 | 2013 | 594 | 0.120 |
Why?
| | Adult | 12 | 2016 | 30544 | 0.120 |
Why?
| | Parity | 1 | 2015 | 98 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2008 | 351 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2019 | 9088 | 0.120 |
Why?
| | Physicians | 1 | 2021 | 772 | 0.110 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1016 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2013 | 35 | 0.110 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 45 | 0.110 |
Why?
| | Survival Rate | 2 | 2015 | 1644 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1139 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 161 | 0.100 |
Why?
| | Tumor Cells, Cultured | 2 | 2012 | 849 | 0.100 |
Why?
| | Stromal Cells | 1 | 2012 | 96 | 0.100 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 82 | 0.100 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 105 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 535 | 0.090 |
Why?
| | Neoplasms, Experimental | 1 | 2012 | 151 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 493 | 0.090 |
Why?
| | Perioperative Period | 1 | 2010 | 49 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2010 | 19 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2010 | 198 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2013 | 1226 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2010 | 59 | 0.080 |
Why?
| | Linear Models | 1 | 2012 | 768 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 797 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 84 | 0.080 |
Why?
| | Academic Medical Centers | 1 | 2012 | 411 | 0.080 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1999 | 153 | 0.080 |
Why?
| | Signal Transduction | 3 | 2020 | 4512 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 2011 | 177 | 0.080 |
Why?
| | Aged | 7 | 2019 | 19069 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 510 | 0.080 |
Why?
| | Middle Aged | 9 | 2019 | 26733 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2013 | 2552 | 0.080 |
Why?
| | Ligation | 1 | 2008 | 75 | 0.080 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2008 | 22 | 0.080 |
Why?
| | Hepatic Artery | 1 | 2008 | 49 | 0.080 |
Why?
| | Hepatic Veins | 1 | 2008 | 29 | 0.070 |
Why?
| | Cholecystectomy | 1 | 2008 | 45 | 0.070 |
Why?
| | Time Factors | 4 | 2012 | 6114 | 0.070 |
Why?
| | CHO Cells | 2 | 1998 | 138 | 0.070 |
Why?
| | Swine | 2 | 2019 | 700 | 0.070 |
Why?
| | Pelvic Bones | 1 | 2009 | 126 | 0.070 |
Why?
| | Cricetinae | 2 | 1998 | 253 | 0.070 |
Why?
| | Cell Movement | 1 | 2010 | 868 | 0.070 |
Why?
| | Safety | 1 | 2008 | 297 | 0.070 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.070 |
Why?
| | Education, Medical | 1 | 2009 | 215 | 0.070 |
Why?
| | Body Weight | 1 | 2010 | 869 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 319 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2009 | 4411 | 0.060 |
Why?
| | Surgical Stapling | 1 | 2005 | 9 | 0.060 |
Why?
| | Prognosis | 2 | 2010 | 3329 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 52 | 0.060 |
Why?
| | Mice, Knockout | 1 | 2010 | 2568 | 0.060 |
Why?
| | Retrospective Studies | 6 | 2021 | 12546 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2186 | 0.050 |
Why?
| | Cytosol | 2 | 2001 | 208 | 0.050 |
Why?
| | Endothelium, Vascular | 2 | 2001 | 847 | 0.050 |
Why?
| | Cells, Cultured | 4 | 1997 | 3885 | 0.050 |
Why?
| | Risk Factors | 5 | 2021 | 8632 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2001 | 60 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 4408 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 1373 | 0.050 |
Why?
| | Egtazic Acid | 1 | 2001 | 44 | 0.050 |
Why?
| | Umbilical Veins | 1 | 2001 | 58 | 0.050 |
Why?
| | Chelating Agents | 1 | 2001 | 65 | 0.050 |
Why?
| | Prospective Studies | 3 | 2021 | 6219 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2021 | 244 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1141 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 19 | 0.040 |
Why?
| | Sialoglycoproteins | 1 | 1999 | 159 | 0.040 |
Why?
| | Chlorhexidine | 1 | 2019 | 22 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 1999 | 72 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 140 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 1999 | 228 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 254 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 289 | 0.040 |
Why?
| | Up-Regulation | 1 | 2001 | 807 | 0.040 |
Why?
| | CD11 Antigens | 1 | 1998 | 30 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2021 | 561 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2001 | 821 | 0.040 |
Why?
| | Models, Animal | 1 | 2019 | 344 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 1999 | 178 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 508 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 1998 | 410 | 0.040 |
Why?
| | Protease Inhibitors | 1 | 1998 | 97 | 0.040 |
Why?
| | Colforsin | 1 | 1997 | 48 | 0.040 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 65 | 0.040 |
Why?
| | Walking | 1 | 2021 | 422 | 0.040 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 181 | 0.040 |
Why?
| | Cell Adhesion | 1 | 1998 | 431 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 2968 | 0.030 |
Why?
| | Ultrafiltration | 1 | 1996 | 27 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 80 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 610 | 0.030 |
Why?
| | Transfection | 1 | 1998 | 866 | 0.030 |
Why?
| | Awards and Prizes | 1 | 1996 | 56 | 0.030 |
Why?
| | Cell Line | 1 | 2001 | 2636 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 1996 | 1982 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 352 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1996 | 195 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2001 | 2285 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1996 | 2785 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 950 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1167 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1230 | 0.030 |
Why?
| | Blood Group Incompatibility | 1 | 2012 | 14 | 0.030 |
Why?
| | Exsanguination | 1 | 2012 | 16 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1262 | 0.020 |
Why?
| | Registries | 2 | 2012 | 1768 | 0.020 |
Why?
| | Inflammation | 3 | 1996 | 2478 | 0.020 |
Why?
| | Adolescent | 3 | 2012 | 17841 | 0.020 |
Why?
| | Hypotension | 1 | 2012 | 116 | 0.020 |
Why?
| | Platelet Count | 1 | 2011 | 81 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2128 | 0.020 |
Why?
| | Shock, Hemorrhagic | 1 | 2012 | 199 | 0.020 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 197 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3046 | 0.020 |
Why?
| | Models, Biological | 1 | 1996 | 1620 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 529 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 953 | 0.020 |
Why?
| | Length of Stay | 1 | 2012 | 962 | 0.020 |
Why?
| | NADPH Oxidases | 2 | 1999 | 120 | 0.020 |
Why?
| | Brain Injuries | 1 | 2012 | 461 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 6345 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 177 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2007 | 139 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2007 | 620 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1796 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 1841 | 0.020 |
Why?
| | United States | 1 | 2021 | 12181 | 0.020 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2005 | 5 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 167 | 0.020 |
Why?
| | Antibodies, Neoplasm | 1 | 2005 | 30 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2005 | 80 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1211 | 0.010 |
Why?
| | Ultrasonography, Interventional | 1 | 2005 | 123 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2005 | 127 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2894 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 455 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 630 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 923 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1692 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1629 | 0.010 |
Why?
| | Infant | 1 | 2012 | 7961 | 0.010 |
Why?
| | Child, Preschool | 1 | 2012 | 9114 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2353 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 1999 | 531 | 0.010 |
Why?
| | Chromatography, Thin Layer | 1 | 1996 | 24 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1996 | 56 | 0.010 |
Why?
| | Neutrophil Activation | 1 | 1996 | 94 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1996 | 785 | 0.010 |
Why?
| | Child | 1 | 2012 | 18412 | 0.010 |
Why?
| | Lipids | 1 | 1996 | 580 | 0.010 |
Why?
|
|
Barnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|